Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.58 |
| ▸ | PKM | P14618 | 2/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 6/20 | 0.45 |
| ▸ | GAA | P10253 | 3/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | CDC7 | O00311 | 1/20 | 0.44 |
| ▸ | DBF4 | Q9UBU7 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 5/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 4/20 | 0.43 |
| ▸ | NPC1 | O15118 | 3/20 | 0.43 |
| ▸ | CASP1 | P29466 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | CASP7 | P55210 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 3/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL29832016 | 0.89 | KDM4E (0.51) | KDM4EPKMALDH1A1HSD17B10GAA | |
| SCHEMBL20267761 | 0.88 | KDM4E (0.53) | KDM4EPKMALDH1A1HSD17B10GAA | |
| SCHEMBL27634383 | 0.86 | KDM4E (0.55) | KDM4EPKMALDH1A1HSD17B10KMT2A | |
| SCHEMBL30007138 | 0.85 | KDM4E (0.50) | KDM4EPKMALDH1A1HSD17B10LMNA | |
| SCHEMBL3333926 | 0.84 | ALDH1A1 (0.50) | KDM4EPKMALDH1A1HSD17B10GAA | |
| SCHEMBL29706037 | 0.84 | CDC7 (0.47) | KDM4EPKMALDH1A1HSD17B10GAA | |
| SCHEMBL27656855 | 0.83 | KDM4E (0.51) | KDM4EPKMALDH1A1HSD17B10LMNA | |
| Formic Acid SCHEMBL31362863 | 0.82 | KDM4E (0.47) | KDM4EPKMALDH1A1HSD17B10GAA | |
| SCHEMBL19940202 | 0.82 | HSD17B10 (0.46) | KDM4EPKMALDH1A1HSD17B10GAA | |
| SCHEMBL2700326 | 0.82 | LMNA (0.49) | KDM4EPKMALDH1A1HSD17B10GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 212 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250212873-A1 | VOLATILE HDAC INHIBITORS FOR THERAPEUTIC AND PLANT APPLICATIONS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2025-07-03 | — | — | US | claimed |
| EP-4482306-A1 | VOLATILE HDAC INHIBITORS FOR THERAPEUTIC AND PLANT APPLICATIONS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2025-01-01 | — | — | EP | claimed |
| CN-118994140-A | Triazole derivative with antidepressant effect, and preparation method and application thereof | 河南科技大学 | 2024-11-22 | — | — | CN | claimed |
| CN-118206505-A | Near infrared fluorescent probe for identifying erythromycin and preparation method and application thereof | 忻州师范学院 | 2024-06-18 | — | — | CN | claimed |
| CN-115772137-B | Preparation method of febuxostat | 济宁晟泰药业有限公司 | 2024-05-10 | — | — | CN | claimed |
| WO-2023192424-A1 | VOLATILE HD AC INHIBITORS FOR THERAPEUTIC AND PLANT APPLICATIONS CROSS-REFERENCE TO RELATED APPLICATION | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-10-05 | — | — | WO | claimed |
| CN-115925649-A | Method for preparing 4-methylthiazole-5-formaldehyde by continuous flow | 深圳市茵诺圣生物科技有限公司 | 2023-04-07 | — | — | CN | claimed |
| CN-115772137-A | Preparation method of febuxostat | 济宁晟泰药业有限公司 | 2023-03-10 | — | — | CN | claimed |
| CN-114262325-A | 3- (3- (heteroaryl) -4-thiazolinone) -N-aryl benzamide compound and synthesis and application thereof | 上海鸿恒生物医药科技有限公司 | 2022-04-01 | — | — | CN | claimed |
| CN-101475541-B | Preparation of 4-methyl thiazole-5-carboxyl acid | HATAI KE YANGZHOU MATERIALS CO LTD | 2011-05-25 | — | — | CN | claimed |
| CN-102002017-A | Method for preparing febuxostat intermediate | BEIJING SECOND PHARMACEUTICAL CO LTD | 2011-04-06 | — | — | CN | claimed |
| CN-101475541-A | Preparation of 4-methyl thiazole-5-carboxyl acid | HATAI KE YANGZHOU MATERIALS CO (CN) | 2009-07-08 | — | — | CN | claimed |
| US-20260060970-A1 | Use of a Therapeutic Agent with Phosphodiesterase-7 Inhibitory Activity for the Treatment and Prevention of Diseases Associated with Chronic Fatigue, Exhaustion and/or Exertional Intolerance | MITODICURE GMBH (DE) | 2026-03-05 | — | — | US | disclosed |
| US-12528781-B2 | Heterocyclic GLP-1 agonists | GASHERBRUM BIO, INC. (US) | 2026-01-20 | — | — | US | disclosed |
| EP-4205741-B1 | CYP2E1 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY-MEDIATED DISEASES | SUZHOU LINGXI BIOTECHNOLOGY CO LTD (CN) | 2025-12-10 | — | — | EP | disclosed |
| EP-4192831-B1 | HETEROCYCLIC GLP-1 AGONISTS | GASHERBRUM BIO INC (US) | 2025-10-22 | — | — | EP | disclosed |
| WO-2002007725-A1 | METHOD FOR TREATING FIBROTIC DISEASES OR OTHER INDICATIONS IC | ALTEON, INC. (US) | 2002-01-31 | — | — | WO | disclosed |
| WO-2001062250-A1 | THIAZOLIUM COMPOUNDS AND TREATMENTS OF DISORDERS ASSOCIATED WITH PROTEIN AGING | ALTEON, INC. (US) | 2001-08-30 | — | — | WO | disclosed |
| US-6277871-B1 | ANTICANCER AGENTS | ABBOTT LABORATORIES | 2001-08-21 | — | — | US | disclosed |
| US-4732977-A | BACTERICIDES | BRISTOL MYERS COMPANY (US) | 1988-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260060970-A1 | Use of a Therapeutic Agent with Phosphodiesterase-7 Inhibitory Activity for the Treatment and Prevention of Diseases Associated with Chronic Fatigue, Exhaustion and/or Exertional Intolerance | PDE5A, PDE4C, PDE12 | KDM4E 2999/4885PKM 1551/4885ALDH1A1 3953/4885 |
| US-12528781-B2 | Heterocyclic GLP-1 agonists | GLP1R, GIPR, VIP | KDM4E 2887/4885PKM 1318/4885ALDH1A1 3780/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.